Drug intelligence / Profile preview

empegfilgrastim

Development stage: Phase 3
Lead developer: Amgen
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Empegfilgrastim is a long-acting, pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) analog. It is designed to stimulate the production, proliferation, and maturation of neutrophils by binding to the G-CSF receptor on hematopoietic cells. This mechanism helps reduce the risk of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy and may also be used for other indications where neutropenia is a concern. Empegfilgrastim acts as an agonist at the granulocyte colony-stimulating factor receptor, activating downstream signaling pathways such as JAK/STAT, PI3K/AKT, and MAPK/ERK to promote neutrophil development and function.

Brand names: Extimia
Other names: MAXY G34

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on empegfilgrastim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on empegfilgrastim.

Explore the full profile